---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-029914"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2025-04-08T23:59:59+00:00"
generated_at: "2026-05-23T19:17:28.530324+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ImmuCell reports record Q1 2025 sales of $8.1M, up 11% YoY

## Summary
- Preliminary unaudited product sales for Q1 2025: $8.1M, up 11% from $7.3M in Q1 2024.
- All-time quarterly sales record; six-month ($15.8M) and twelve-month ($27.3M) periods also record.
- Order backlog reduced to $4.0M as of March 31, 2025, from $4.4M at Dec 31, 2024.
- Annualized Q1 sales were approximately 108% of estimated $30M annual capacity.
- NADA submission for Re-Tain progressing; critical path remains inspection at contract manufacturer.

## SEC filing metadata
- accession: 0001213900-25-029914
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2025-04-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390025029914/0001213900-25-029914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390025029914/ea0237552-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-029914
- JSON: https://secwatch.observer/filing/0001213900-25-029914.json
- Plain text: https://secwatch.observer/filing/0001213900-25-029914.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.